徐瑜, 毕宇芳, 王卫庆, 等. 中国成人糖尿病流行与控制现状——2010年中国慢病监测暨糖尿病专题调查报告解读[J]. 中华内分泌代谢杂志, 2014, 30(3): 184-186. [2]Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomized, parallel-group, open-label trial[J]. Int J Clin Praet, 2011, 65(4): 397-407. [3]Monami M, Cremasco F, Lamanna C, et al. Glueagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials[J]. Exp Diabetes Res, 2011, 2011: 215764. [4]Zhou J, Cai Z H, Li L, et al. Preparation and PEGylation of exendin-4 peptide secreted from yeast Pichia pastoris[J]. Eur J Pharm Biopharm, 2009, 72(2): 412-417. [5]Gao W, Jusko W J. Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats[J]. J Pharmacol Exp Ther, 2011, 336(3): 881-890. [6]Ai G, Chen Z, Shan C, et al. Single- and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys[J]. Int J Pharm, 2008, 353(1/2): 56-64. [7]Apovian C M, Bergenstal R M, Cuddihy R M, et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes[J]. Am J Med, 2010, 123(5): 468.e9-468.e17. [8]黄艾平, 张弛, 陈丹丹, 等. 艾塞那肽治疗对2型糖尿病患者缓解期的影响研究[J]. 中国药房, 2012, 23(22): 2059-2062. [9]Shyangdan D S, Royle P L, Clar C, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis[J]. BMC Endocr Disord, 2010, 10: 20. [10]Bunck M C, Diamant M, Corner A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial[J]. Diabetes Care, 2009, 32(5): 762-768. [11]Bradley D P, Kulstad R, Schoeller D A. Exenatide and weight loss[J]. Nutrition, 2010, 26(3): 243-249. [12]Henry R R, Ratner R E, Stonehouse A H, et al. Exenatide maintained glycemic control with associated weight reduction over 2 years inpatients with type 2 diabetes[C]. Washington: American Diabetes Association, 66th Scientific Sessions, 2006. [13]Hsieh J, Longuet C, Baker C L, et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice[J]. Diabetologia, 2010, 53(3): 552-561. [14]Roubicek T, Mraz M, Bartlova M, et al. The influence of 6-months treatment with exenatide on type 2 diabetes mellitus compensation, anthropometric and biochemical parameters[J]. Vnitr Lek, 2010, 56(1): 15-20. [15]Mundil D, Cameron-Vendrig A, Husain M. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects[J]. Diab Vasc Dis Res, 2012, 9(2): 95-108. [16]Davis S N, Johns D, Maggs D, et al. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents[J]. Diabetes Care, 2007, 30(11): 2767- 2772. [17]Chen K, Yu X, Murao K, et al. Exendin-4 regulates GLUT2 expression via the CaMKK/CaMKIV pathway in a panacreatic beta-cell line[J]．Metabolism, 2011, 60(4): 579-585.
